Trial Profile
A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Zoledronic acid (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 04 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2027.
- 23 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.